Olema Pharmaceuticals (OLMA)
(Delayed Data from NSDQ)
$4.64 USD
-0.08 (-1.69%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $4.63 -0.01 (-0.22%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Olema Pharmaceuticals, Inc.'s return on equity, or ROE, is -42.31% compared to the ROE of the Medical - Biomedical and Genetics industry of -61.64%. While this shows that OLMA has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
OLMA 4.64 -0.08(-1.69%)
Will OLMA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OLMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OLMA
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?
Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet
OLMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
Other News for OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | OLMA Stock News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | OLMA Stock News
Olema Pharmaceuticals Holds Annual Stockholders Meeting
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | OLMA Stock News
12 Health Care Stocks Moving In Monday's Intraday Session